Chen Guo-bao, Wei Lian-bo, Xiao Wei, Long Hai-bo
Center of Integrated Traditional and Western Nephrology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China.
Nan Fang Yi Ke Da Xue Xue Bao. 2006 Apr;26(4):526-8.
To study the mechanism of Shenkangwan (SKW) in treating early diabetic nephropathy (DN).
The effect of SKW on NO and transforming growth factor (TGF)-beta(1) production by the mesangial cells (MCs) of rats with early diabetic nephropathy was evaluated with serum pharmacological method.
Compared with normal serum, the SKW-containing serum dose- and time-dependently inhibited TGF-beta(1) excretion and increased NO production in the MCs of rats with early DN (P<0.05 and P<0.01, respectively).
The therapeutic effect of SKW on early DN may rely on the balance modulation of cytokine network by increasing NO production and decreasing TGF-beta(1) excretion to prevent cytokine-induced damage of the MCs.
研究肾康丸（SKW）治疗早期糖尿病肾病（DN）的机制。
采用血清药理学方法，评估肾康丸含药血清对早期糖尿病肾病大鼠系膜细胞（MCs）产生一氧化氮（NO）和转化生长因子（TGF）-β1的影响。
与正常血清相比，含肾康丸血清能剂量和时间依赖性地抑制早期糖尿病肾病大鼠系膜细胞中TGF-β1的分泌，并增加NO的产生（分别为P<0.05和P<0.01）。
肾康丸对早期糖尿病肾病的治疗作用可能依赖于通过增加NO的产生和减少TGF-β1的分泌来调节细胞因子网络平衡，从而防止细胞因子诱导的系膜细胞损伤。
